Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig

David C. Underwood, Steven Bochnowicz, Ruth R. Osborn, Charles J. Kotzer, Mark A. Luttmann, Douglas W.P. Hay, Peter D. Gorycki, Siegfried B. Christensen and Theodore J. Torphy
Journal of Pharmacology and Experimental Therapeutics December 1998, 287 (3) 988-995;
David C. Underwood
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Bochnowicz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth R. Osborn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles J. Kotzer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Luttmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas W.P. Hay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter D. Gorycki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siegfried B. Christensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theodore J. Torphy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We evaluated the airway activity of the novel phosphodiesterase type 4 inhibitor SB 207499 [Ariflo;c-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl-r-1-cyclohexane carboxylic acid)], in the guinea pig. Ovalbumin (OA)-induced contractions of guinea pig isolated tracheal strips were inhibited by SB 207499 with an EC50 of 1 μM but had little or no effect on exogenous agonist-induced contraction, which suggests that its effect on OA-induced contraction in vitro is primarily due to inhibition of mediator release from mast cells. In anesthetized guinea pigs, SB 207499 inhibited OA-induced bronchoconstriction with i.v. and p.o. ID50 values of 1.7 and 17 mg/kg, respectively. At 1, 3 and 6 hr after SB 207499 (30 mg/kg p.o.), OA-induced bronchospasm was inhibited by 92%, 70% and 58%, respectively, corresponding to elevated plasma concentrations of 1.62 ± 0.19, 1.65 ± 0.29 and 0.93 ± 0.24 μg/ml, respectively, of SB 207499. SB 207499 also inhibited house dust mite-induced bronchoconstriction (ID50 = 0.9 mg/kg i.v. and 8.9 mg/kg p.o.). In contrast to its lack of bronchorelaxant activityin vitro, SB 207499 inhibited bronchospasm induced by i.v. leukotriene D4 (LTD4) [ID50 = 3 mg/kg i.v.]. The bronchorelaxant effect of i.v.-administered SB 207499 was at least additive with that of salbutamol in reversing infused histamine-enhanced airway tone, but it did not alter base line or enhance salbutamol-induced cardiovascular effects. In conscious guinea pigs, SB 207499 (10 or 30 mg/kg p.o.), 1 hr before antigen or LTD4 challenge, markedly reduced bronchospasm and subsequent eosinophil influx as measured by bronchoalveolar lavage 24 hr after provocation. SB 207499 administered after OA or LTD4 challenge also reduced airway eosinophilia measured at 24 hr after OA challenge or 96 hr after LTD4 challenge. These results, coupled with the broad anti-inflammatory activity of SB 207499 previously described (Barnette et al., 1998), suggest that SB 207499 will be useful in the treatment of asthma and other inflammatory disorders.

Footnotes

  • Send reprint requests to: David C. Underwood, Ph.D., SmithKline Beecham Pharmaceuticals, Pulmonary Pharmacology, UW2532, P.O. Box 1539, King of Prussia, PA 19406

  • Abbreviations:
    PDE4
    phosphodiesterase type 4
    OA
    ovalbumin
    HDM
    house dust mite
    LTD4
    leukotriene D4
    SB 207499 (Ariflo)
    c-4-cyano-4-3-cyclopentyloxy-4-methoxyphenyl-r-1-cyclohexane carboxylic acid
    BAL
    bronchoalveolar lavage
    • Received November 26, 1997.
    • Accepted July 10, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 287, Issue 3
1 Dec 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig

David C. Underwood, Steven Bochnowicz, Ruth R. Osborn, Charles J. Kotzer, Mark A. Luttmann, Douglas W.P. Hay, Peter D. Gorycki, Siegfried B. Christensen and Theodore J. Torphy
Journal of Pharmacology and Experimental Therapeutics December 1, 1998, 287 (3) 988-995;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig

David C. Underwood, Steven Bochnowicz, Ruth R. Osborn, Charles J. Kotzer, Mark A. Luttmann, Douglas W.P. Hay, Peter D. Gorycki, Siegfried B. Christensen and Theodore J. Torphy
Journal of Pharmacology and Experimental Therapeutics December 1, 1998, 287 (3) 988-995;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Mechanisms of 5-Hydroxytryptamine2A Receptor Activation of the Mitogen-Activated Protein Kinase Pathway in Vascular Smooth Muscle
  • Interactive Role for Neurosteroids in Ethanol Enhancement of γ-Aminobutyric Acid-Gated Currents from Dissociated Substantia Nigra Reticulata Neurons
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics